New Drug IND

Related by string. * new . newer . news . NEWS . Newer : NEW YORK BUSINESS WIRE . STOCKS NEWS US . New Year Eve . Quote Chart News . BREAKING NEWS UPDATE / Drugs . DRUG . drugs . DRUGS . Druger : Drug Task Force . Prescription Drug User Fee . Drug Enforcement Administration . Drug Administration FDA / In . INS . Ind . in : R Ind . SIMULATED TRADING PROGRAMS IN . REMAINS IN EFFECT UNTIL . IN NO EVENT * *

Related by context. All words. (Click for frequent words.) 68 Investigational 64 IND 63 IND Investigational New 62 New Drug Application 60 Investigational Device Exemption IDE 59 Phase IIb clinical 59 INDs 59 Application BLA 58 initiate Phase 58 pivotal Phase III 58 Phase III clinical 57 Investigational Device Exemption 57 Phase IIa 57 Phase IIa clinical 57 Premarket Approval PMA 57 IND submission 57 Biologics License Application BLA 57 IND enabling 57 Zenvia ™ 56 Marketing Authorization Application MAA 56 registrational 56 Phase 2b clinical 56 Phase 2a clinical 56 Phase III clinical trials 56 investigational 56 Phase Ib 55 Phase IIb 55 Biologics License Application 55 Marketing Authorization Application 55 Anturol 55 phase Ib clinical 55 MEK inhibitor 54 PNP inhibitor 54 Clinical Trial Application 54 submit Biologics License 54 Anturol ® 54 phase IIb clinical 54 Phase IIa trials 54 investigational drug 54 phase IIa clinical 54 CEQ# 54 Phase IIa trial 54 phase IIa 54 mitogen activated ERK kinase 54 Biologic License Application BLA 54 k premarket 54 Junovan TM 54 preclinical 54 Fx #A 54 CB2 selective receptor agonist 54 FOLOTYN ® 53 submitted Biologics License 53 Phase III pivotal 53 multiple ascending dose 53 Panzem R 53 Zelrix 53 Iluvien ® 53 Zingo TM 53 Phase 2a 53 injectable formulation 53 confirmatory Phase III 53 CIP TRAMADOL ER 53 ATryn R 53 Soliris TM eculizumab 53 oral formulation 53 rolling Biologics License 53 TKM Ebola 52 supplemental Biologics License Application 52 Phase #b/#a clinical 52 IAP inhibitor 52 MOR# 52 miconazole Lauriad R 52 vilazodone 52 Zenvia TM 52 Cloretazine ® 52 Phase 2b trial 52 BEMA Fentanyl 52 Luveniq 52 subcutaneous formulation 52 NDA submission 52 StaphVAX R 52 PDE4 inhibitor 52 oral prodrug 52 Lenocta TM 52 liver resection surgeries 52 candidates bavituximab 52 pivotal Phase 52 dextromethorphan quinidine 52 Phase Ib clinical trials 52 CBLB# 52 investigational compound 52 investigational pan BCR 52 POSIDUR TM ELADUR TM 52 pseudobulbar affect PBA 52 lintuzumab SGN 52 alvimopan 52 Linjeta TM 52 virus HCV protease inhibitor 52 confirmatory Phase 3 52 PLK1 SNALP 52 Friedreich Ataxia FRDA 52 refractory Hodgkin lymphoma 52 Phase IIIb clinical 52 ORE# 52 Familial Adenomatous Polyposis FAP 51 sodium Injection 51 TELINTRA 51 supplemental biologics 51 acyclovir Lauriad R 51 Phase II 51 Phase 1b clinical 51 diarrhea predominant irritable 51 lucinactant 51 CORT # 51 Soliris eculizumab 51 tiapamil 51 Phase IIb trial 51 sNDA 51 humanized monoclonal antibody 51 REMOXY R 51 recombinant human 51 Phenoptin 51 candidate REP# 51 Fentanyl TAIFUN R 51 GLP toxicology studies 51 Marqibo 51 Nasdaq VRTX 51 PDX pralatrexate 51 methylnaltrexone bromide 51 Ceplene ® histamine dihydrochloride 51 JAK inhibitor 51 initiate Phase 1b 51 Market Approval PMA 51 Phase 1b 51 LEVADEX TM 51 tafamidis 51 Phase Ib clinical 51 dermal patch 51 Esbriet pirfenidone 51 gastrointestinal disorders characterized 51 NASDAQ OSIR 51 opioid induced constipation 51 histone deacetylase HDAC inhibitor 51 Ketotransdel ® 51 Phase III 51 SILENOR TM 51 R#/MEM # 51 Phase 2b 51 Exherin TM 51 maribavir 51 TKM PLK1 51 Corlux 50 Cellegesic 50 Staccato loxapine 50 Augment TM 50 ATryn ® 50 NP2 Enkephalin 50 Biologic License Application 50 orphan designation 50 Oracea TM 50 initiate Phase IIa 50 Voraxaze 50 include Phenoptin TM 50 ophthalmic indications 50 PrevOnco ™ 50 Phase 2b clinical trials 50 Marketing Authorisation Application 50 Shigamabs R 50 TSX DND 50 relapsed refractory multiple myeloma 50 Nerve Targeting Drug 50 Oxytrex TM 50 TKM ApoB 50 Marketing Authorisation Application MAA 50 HCV protease inhibitor 50 intravenous acetaminophen 50 adecatumumab MT# 50 AQ4N 50 PREOS R 50 Application MAA 50 BLA submission 50 refractory chronic lymphocytic 50 lomitapide 50 post herpetic neuralgia PHN 50 Cannabinor 50 cannabinor 50 Rhucin ® recombinant 50 ruxolitinib 50 Aerosurf 50 NASDAQ ARRY 50 Orphan Drug Designation 50 GED aPC 50 Phase III Pivotal 50 Onconase 50 Phase IIb clinical trials 50 OLpur TM H2H 50 JOULFERON 50 hypoxia activated prodrug 50 drug GAP #B# 50 GENTAMICIN SURGICAL IMPLANT 50 TKB# 50 PREOS 50 DC Bead 50 Vicinium TM 50 Glybera R 50 investigational humanized monoclonal antibody 50 Personalized Immunotherapy 50 inhaled liposomal ciprofloxacin 50 release intravitreal insert 50 Civacir 50 Trofex 50 investigational oral 50 Phase Ia 50 initiated Phase Ib 50 EVIZON TM squalamine lactate 50 Restanza 50 Shigamabs ® 50 HGS# 50 oritavancin 50 Phase Ib study 50 trastuzumab DM1 T DM1 50 Nasdaq PGNX today 50 ALN TTR# 50 pivotal bioequivalence 50 faropenem medoxomil 50 antibody MAb 50 Initiate Phase 50 prGCD 50 Phase 1a clinical 50 preclinical studies 50 NEBIDO R 50 drug ISA# 50 Troxatyl 50 Prodarsan ® 50 Anturol TM 50 PMA submission 50 Premarket Approval Application 50 Orphan Drug status 50 targeted radiotherapeutic 50 ADVEXIN p# therapy 50 granted Ortec 50 BLA filing 50 Phase 2b study 50 ATL# [001] 50 AAG geldanamycin analog 49 teduglutide 49 orphan drug 49 Orphan Drug designations 49 relapsed multiple myeloma 49 carfilzomib 49 Actemra tocilizumab 49 OROS R Hydromorphone 49 PD LID 49 Sanvar R 49 Nabi HB Intravenous 49 GTC recombinant human 49 sBLA 49 IMA# 49 PRX # 49 Rhucin ® 49 Fast Track Designation 49 SUVN 49 Aryplase 49 SinuNase ™ 49 MAGE A3 ASCI 49 MONOVISC 49 Fast Track designations 49 reslizumab 49 Orphan Drug 49 PSN# [002] 49 Nasdaq HALO 49 FACTIVE R gemifloxacin 49 Fibrillex TM 49 autologous cell 49 ALN TTR 49 Omacetaxine 49 candidate Zenvia 49 Cladribine Tablets 49 diabetic neuropathic pain 49 CD# CEA 49 Archexin 49 Onalta ™ 49 lexidronam injection 49 NEUMUNE 49 initiate Phase Ib 49 cutaneous T 49 candidate WF# 49 AeroLEF 49 Onrigin 49 Cotara R 49 dose escalation trial 49 ganetespib 49 dose escalation clinical 49 Phase Ib IIa 49 XOMA 3AB 49 LUVENIQ 49 subcutaneous RELISTOR 49 Phase #b/#a 49 candidate XP# 49 Fodosine 49 overactive bladder AA# 49 Pruvel 49 PHX# 49 Serostim ® 49 methylnaltrexone 49 ADVANCE PD 49 VEGF Trap 49 ALN PCS 49 XL# anticancer compounds 49 AP# [003] 49 Surfaxin LS 49 systemic anaplastic large 49 VALSTAR R 49 PI3K/Akt pathway inhibitor 49 TRANSDUR TM Sufentanil 49 Emezine 49 non nucleoside inhibitor 49 RDEA# 49 humanized anti 49 DAVANAT R 49 FDA Approvable Letter 49 forodesine hydrochloride 49 selective immunoproteasome inhibitor 49 oral ridaforolimus 49 Tramadol ER 49 phase Ib 49 MAA submission 49 Phase IIb trials 49 Phase III confirmatory 49 tezampanel 49 anti botulism antibody 49 ABL inhibitor 49 sNDA submission 49 mesylate tablets 49 GTC recombinant form 49 Increlex TM 49 cinacalcet HCl 49 alogliptin 49 Qutenza TM 49 LymphoStat B TM 49 REMOXY ® 49 Biological License Application 49 Orathecin 49 Humanitarian Device Exemption 49 antibiotic candidate Ramoplanin 49 cell lymphoma CTCL 49 Panzem 49 ONCONASE 49 Protexia ® 49 Enkephalin 49 dyskinesia PD LID 49 Resten NG 49 Iluvien 49 ofatumumab HuMax CD# 49 ThermoDox R 49 NGX# 49 Loramyc R 49 thorough QT 49 AEG# 49 tamibarotene 49 Icatibant 49 delta opioid receptor 49 TRANSDUR Sufentanil 49 VitiGam 49 Phase 2a trial 49 nicotinic alpha 7 49 Amoxicillin PULSYS 49 PHASE III 49 Arzerra ofatumumab 49 investigational hepatitis B 49 novel mTOR inhibitor 49 ApoB SNALP 49 Drug Submission 49 RNAi therapeutic targeting 49 vapreotide acetate 49 topical anti infective 49 Homspera 49 Guanilib 49 generation purine nucleoside 48 dasatinib Sprycel ® 48 CORLUX 48 NanoTab 48 Teflaro 48 HCV polymerase inhibitor 48 MT#/MEDI-# 48 product platforms AZX# 48 anticancer agent 48 FRDA 48 investigational hepatitis C 48 Clevudine 48 Loramyc 48 APEX PD 48 MEK inhibitor RDEA# 48 Remoxy TM 48 Cinryze TM C1 inhibitor 48 Augment ™ 48 Cleviprex TM clevidipine 48 opioid induced bowel dysfunction 48 Files Investigational 48 anticancer compound 48 Fortigel 48 OncoVEX GM CSF 48 vinorelbine emulsion 48 By JAMAAL ABDUL 48 MOZOBIL 48 ALVESCO R 48 IND CTA 48 PrevOnco 48 sulodexide 48 mGluR5 negative 48 Fentanyl Taifun 48 application sNDA 48 pediatric glioma 48 preclinical toxicology 48 TYZEKA 48 diabetic macular edema DME 48 IIa trial 48 ATryn ® GTC recombinant 48 CRMD# 48 compound ISA# 48 potently inhibit 48 Alzhemed TM 48 Dacetuzumab 48 Pivotal Phase III 48 non nucleoside HCV 48 Initiates Phase II 48 Dalbavancin 48 allosteric modulator NAM 48 hematological malignancies 48 orally administered inhibitor 48 Nimotuzumab 48 Vilazodone 48 IDX# 48 phase 2a 48 Cutanea Life Sciences 48 anthrax monoclonal antibody 48 memantine HCl 48 opioid induced constipation OIC 48 AA amyloidosis 48 % uracil topical 48 dihydrochloride Phase 3 48 Biologics License Applications 48 topically applied SEPA 48 Oscient Pharmaceuticals Corporation 48 Augment Bone Graft 48 Anthim 48 ofatumumab 48 histamine dihydrochloride 48 AEOL # 48 huC# DM4 48 Ceflatonin ® 48 Allovectin 7 R 48 apaziquone 48 clinical trial 48 Genasense R oblimersen 48 liposomal formulation 48 multicenter Phase 48 postherpetic neuralgia PHN 48 Phase Ib II 48 ILUVIEN ® 48 AMPAKINE CX# 48 carcinogenicity study 48 Nasdaq PCYC 48 Ceflatonin R 48 investigational antiplatelet agent 48 sarcoma melanoma 48 RNA interference RNAi therapeutics 48 Annamycin 48 acyclovir Lauriad ® 48 candidate brentuximab vedotin 48 Phase IIa clinical trials 48 CDP# 48 initiate Phase IIb 48 JZP 48 SYCREST 48 RhuDex ® 48 ecallantide 48 NYSE Amex PTN 48 Inc. Nasdaq IDMI 48 Cimzia TM 48 EOquin 48 CCR5 antagonist 48 EVIZON TM 48 TSX YM AIM 48 Bone Graft 48 Fast Track designation 48 SparVax TM 48 JAK2 Inhibitor 48 RSD# oral 48 TBC# 48 tezampanel NGX# 48 phase IIb study 48 forodesine HCl 48 multicenter Phase III 48 synthetic retinoid 48 CryoSeal FS System 48 Phase IIb Trial 48 Xcytrin R 48 Entereg TM 48 P#X# antagonist 48 registrational studies 48 BYDUREON 48 Prodarsan R 48 LHRH antagonist 48 polyneuropathy HIV DSP 48 Bronchitol 48 treat opioid induced 48 oral methylnaltrexone 48 Linaclotide 48 Parkinson disease levodopa induced 48 hoFH 48 Genasense ® oblimersen 48 SinuNase TM 48 Somatuline Depot 48 randomized Phase 48 clevudine 48 Ketotransdel 48 ThermoDox ® 48 Onalta 48 mesylate tablets approved 48 Tarvacin TM 48 Anidulafungin 48 PROGENSA R 48 selective androgen receptor modulator 48 VQD 48 CORLUX CORT # 48 novel histone deacetylase 48 Neo Kidney Augment 48 CCR5 mAb 48 Apricus Bio 48 Diabetic Macular Edema 48 NEBIDO 48 Phase 1b trial 48 refractory APL 48 S OMX GEN 48 Rhucin R 48 Phase lll 48 Opterone R 48 phase IIb 48 investigational HCV polymerase 48 radiation sensitizer 48 investigational oral hepatitis C 48 ALKS 48 intranasal formulation 48 CG# [003] 48 Prochymal TM 48 GATTEX 48 inhaled formulation 48 Market Authorization Application 48 eprodisate KIACTA TM 48 AeroLEF TM 48 Neurodex TM 48 arimoclomol 48 Silodosin 47 Orphan Drug designation 47 selective A2A adenosine receptor 47 NasdaqGM NTEC today 47 PF # [002] 47 dose escalation study 47 C1 inhibitor rhC1INH 47 hypoparathyroidism 47 Simulect 47 zolpidem tartrate sublingual tablet 47 autologous cellular therapies 47 Roche PEGASYS R 47 Drug Applications INDs 47 Inc. AMEX YMI 47 Phase IIB 47 Phase III trials 47 BEMA Buprenorphine 47 arsenic trioxide injection 47 post operative ileus 47 SparVax ™ 47 Therapik R 47 Curaxin CBLC# 47 linaclotide 47 gemcitabine Gemzar ® 47 topical non steroidal 47 INKP 47 Biologics Licensing 47 Tarsa Therapeutics 47 cetrorelix pamoate 47 Urocidin 47 Protectan CBLB# 47 next generation URAT1 47 refractory gout 47 Nasdaq PPHM 47 single ascending dose 47 oncolytic virus therapy 47 immunosuppressive compound 47 CVBT #B 47 Nexavar ® 47 Tamibarotene 47 oral nucleoside analogue 47 OMNARIS HFA 47 Dacogen injection 47 ATPace TM 47 GLP toxicology 47 crofelemer 47 ISENTRESS raltegravir 47 MT# MEDI 47 ketolide antibiotic 47 AZX# 47 Zorbtive TM 47 Phase IIb Clinical Trial 47 MIS# 47 balsalazide tablet 47 CD# monoclonal antibody 47 Hsp# Inhibitor 47 PXD# 47 multicenter Phase II 47 Ofatumumab 47 anti CD3 monoclonal 47 LibiGel ® 47 novel VDA molecule 47 Staphylococcus aureus Polysaccharide Conjugate 47 midstage trials 47 EV# vaccine 47 Linjeta ™ 47 Acute Radiation Syndrome ARS 47 GATTEX ® 47 Phase 2a clinical trials 47 TAXUS Element Stent System 47 mTOR inhibitor 47 Nanobody 47 Oral BDP 47 apoptosis inducer 47 Zenvia Phase III 47 ARIKACE 47 class oral heparinoid 47 intravenous formulation 47 Allovectin 7 47 PROMUS Element Stent System 47 candidates Augment ™ 47 Phase IIb III 47 CIMZIA r 47 Australian Therapeutic Goods 47 Aurexis 47 Veronate 47 MGCD# [001] 47 IAP inhibitors 47 NDA resubmission 47 painful diabetic neuropathy 47 Exalgo TM 47 Marketing Approval PMA 47 Xyfid TM 47 Hepatitis C virus HCV 47 ICA # 47 EVIZON ™ 47 Curaxin 47 Pharmion Corporation 47 lead Aganocide compound 47 granulated mesalamine 47 INCB# [001] 47 PANVAC VF 47 HIV integrase inhibitor 47 molecular imaging radiopharmaceutical 47 investigational atypical antipsychotic 47 dacetuzumab SGN 47 leading oral taxane 47 Nasdaq MBRX announced 47 drug conjugate 47 Prodarsan 47 Allovectin 7 ® 47 Kamada AAT 47 TELCYTA 47 URG# 47 visilizumab 47 ARRY # 47 preclinical efficacy 47 JAK1 47 catheter occlusion 47 mGluR2 positive 47 cGMP manufacture 47 lymphoid malignancies 47 Spiegelmer ® 47 sapropterin dihydrochloride 47 RIGScan ™ 47 Generx ™ 47 Restanza TM 47 RenaZorb TM 47 Telavancin 47 Aztreonam lysine 47 ELADUR ™ 47 OAB overactive bladder 47 HCV NS5B polymerase 47 NASDAQ PSDV ASX 47 IPLEX 47 ELACYT 47 voclosporin 47 taliglucerase alfa 47 Elagolix 47 ZEVALIN ® 47 sorafenib tablets 47 IMiDs 47 octreotide implant 47 human C1 inhibitor 47 ospemifene 47 immunomodulator 47 silodosin 47 apoptosis proteins 47 KALBITOR ® 47 SNT MC# 47 Dr. Arndt Schottelius 47 forodesine 47 Ophena TM 47 Kuvan TM sapropterin 47 delivers fluocinolone acetonide FA 47 Injectable Bone Graft 47 Inc. NASDAQ ANPI 47 REGENERX BIOPHARMACEUTICALS INC. 47 Solazed TM 47 sterile lidocaine patch 47 Amigal TM 47 clofarabine 47 JAK2 inhibitor 47 Ceflatonin 47 Cyclooxygenase Inhibiting Nitric Oxide 47 oncology indications 47 cutaneous T cell 47 DOS# 47 markets Gelclair R 47 Augment Injectable 47 Solzira TM 47 LymphoStat B belimumab 47 rALLy clinical trial 47 oral deforolimus 47 cyclobenzaprine hydrochloride extended 47 Phase IIa Clinical Trial 47 ONSOLIS TM 47 compound PMX # 47 Nasdaq DVAX 47 Oxycyte ® 47 Files IND 47 PEG PAL 47 Chaim Lebovits President 47 dose escalation Phase 47 Anavex #-# 47 diagnostic molecular imaging 47 non constipation irritable 47 CF# [002] 47 allosteric modulator PAM 47 Onco TCS 47 thrombin component 47 Pirfenidone 47 Acute Myeloid Leukemia AML 47 Proxinium TM 47 GALNS 47 Project QTDP program 47 IMiDs R 47 incyclinide 47 compound INCB# 47 ZALBIN 47 Cinryze TM 47 placebo controlled Phase 47 Hedgehog pathway inhibitor 47 Tarceva TM 47 KNS # 47 HDAC Inhibitor 47 NASDAQ CXSP announced 47 Kit CD# positive 47 Loramyc ® 47 OTCBB HXBM developer 47 inhaled antibiotic 47 NASDAQ PGNX 47 Raptiva ® 47 rusalatide acetate 47 Camvia 47 FDA Investigational Device 47 exemption IDE 47 Flutiform ™ 47 LOMUCIN TM 47 Golimumab 47 sumatriptan DosePro 47 Laquinimod 47 Phase 1a 47 GLPG# 47 QNEXA 47 oral proteasome inhibitor 47 omacetaxine 47 Factor VIIa 47 castrate resistant prostate cancer 47 oxymorphone ER 47 STEDESA 47 IMVAMUNE R 47 Certolizumab pegol 47 Genasense oblimersen sodium Injection 47 R roscovitine CDK cyclin 47 BEMA TM Fentanyl 47 nasal calcitonin product 47 TRISENOX ® 47 Genasense ® 47 SURFAXIN 47 SonoLysis 47 Alvesco R 47 Silenor ® doxepin 47 PROPEL trial 47 HepeX B TM 47 Mycograb 47 NEUGENE R 47 Topical Interferon Alpha 2b 47 OTCBB PYTO 47 Aplidin 47 THALOMID 47 ANTEGREN 47 topically administered 47 Cinryze ™ 47 Abstral 47 OTCQX QRXPY 47 INSPIRE Trial Phase III 47 pralatrexate injection folate analogue 47 Inc. Nasdaq VVUS 47 Dupuytren Contracture 47 novel orally administered 47 AzaSite Plus 47 WX UK1 47 amifampridine phosphate 47 Diamyd ® 47 Bendamustine 47 Fast Track Status 47 Fodosine TM 47 Premarket Notification 47 CIP Fenofibrate 46 ABRAXANE ® 46 GLP1 INT TM 46 Nasdaq VICL 46 eniluracil 46 Somatuline R Autogel R 46 PNT# 46 SciClone Pharmaceuticals Inc. 46 Neo Urinary Conduit 46 laninamivir 46 ACV1 46 R bendamustine hydrochloride 46 REPEL CV 46 ongoing Phase 1b 46 immunotherapeutic vaccine 46 oral antiviral 46 exocrine pancreatic insufficiency EPI 46 trodusquemine MSI 46 MCSP respectively 46 TACI Ig 46 erlotinib Tarceva ® 46 PKC# 46 prokinetic agent 46 Protexia R 46 Manja Bouman CEO 46 Glybera 46 Aviptadil 46 CCR9 antagonist 46 Cimzia ® 46 VALSTAR 46 dalbavancin 46 Neovasc Reducer 46 PRNewswire FirstCall OncoGenex Pharmaceuticals 46 Sym# 46 samarium Sm 46 non alcoholic steatohepatitis 46 RANK Ligand inhibitor 46 motexafin gadolinium Injection 46 huN# DM1 46 male hypogonadism PRO 46 Evoltra ® 46 Crofelemer 46 lenalidomide Revlimid R 46 autologous cellular immunotherapy 46 Subpart E 46 L Annamycin 46 containing granisetron 46 rufinamide 46 generation PNP inhibitor 46 ANDAs 46 Bioral Amphotericin B 46 acetonide FA 46 Abiraterone acetate 46 small molecule chemotherapeutic 46 Thrombin topical Recombinant 46 brentuximab vedotin SGN 46 Raptiva R 46 Keppra ® levetiracetam 46 Lenocta 46 Rhucin 46 Testosterone MDTS ® 46 IMPACT DCM trial 46 OMAPRO ™ 46 Locteron ® 46 albinterferon alfa 2b 46 Diabetic Macular Edema DME 46 pharmacological chaperone 46 NASDAQ IDEV 46 NTx TM -# 46 relapsing multiple sclerosis 46 ROTATEQ 46 Alpharadin 46 severe gastroparesis 46 Excellagen 46 Initiate Clinical Trial 46 vaccine GRNVAC1 46 MOVIPREP R 46 MyVax R 46 Mepact 46 MORAb 46 VEGFR2 inhibitor 46 Cethrin 46 compound COTI 46 Zavesca ® 46 brivaracetam 46 Microcyn Technology 46 Arikace 46 generation URAT1 inhibitor 46 StemEx R 46 registrational trial 46 Vion Pharmaceuticals 46 CORTOSS 46 Initiates Enrollment 46 melanocortin receptor agonists 46 alvespimycin 46 Intravenous Human 46 Initiated Phase 46 NASDAQ ISPH announced 46 ELND# 46 Zalypsis 46 candidate NGX 46 Entereg R 46 highly purified pasteurized 46 rheumatoid arthritis psoriatic arthritis 46 Inc. Nasdaq CYCC 46 HepaGam B TM 46 Behcet uveitis 46 Lixivaptan 46 Junovan 46 SomatoKine 46 PRTX 46 severe oral mucositis 46 Corp. NASDAQ CRME 46 human monoclonal antibody 46 Collategene TM 46 OrCel ® 46 diabetic peripheral neuropathic DPN 46 blinded randomized placebo controlled 46 NM# [001] 46 QNEXA ® 46 Acetavance TM 46 orBec 46 Inc. Nasdaq RDEA 46 DOR# 46 Clinical Trial 46 personalized cellular immunotherapy 46 mertansine 46 ENTEREG ® 46 IIa clinical 46 CryoCor Cardiac Cryoablation System 46 Prednisporin TM 46 torezolid phosphate 46 Nasdaq MBRX 46 omacetaxine mepesuccinate 46 Alinia 46 CNW YM BioSciences 46 intravenous ghrelin agonist 46 PRNewswire FirstCall Genta Incorporated 46 SUTENT ® 46 severe hypercholesterolemia 46 sNDAs 46 TRACON Pharmaceuticals Inc. 46 COPREXA 46 PROVENGE ® 46 oxybutynin ATD TM 46 Submits Investigational 46 Nasdaq OSCI 46 Hepatitis C HCV 46 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 46 Expression Genetics 46 Urokinase 46 multiple myeloma MM 46 RAPTIVA 46 Aurora kinase inhibitor 46 AnGes 46 BEMA ® 46 Pharmos pipeline 46 recombinant biopharmaceutical 46 opioid bowel dysfunction 46 ASONEP TM 46 Tectin TM 46 Addrenex 46 dependent kinase inhibitor 46 BEMA TM Buprenorphine 46 Maribavir 46 Nasdaq KERX 46 human lactoferrin 46 Trizytek 46 Daclizumab 46 Nasdaq VNDA 46 Frova ® 46 Aloxi Injection 46 ATL# [002] 46 MEND CABG II 46 Empatic TM 46 Orphan Drug Status 46 factor TNF receptor

Back to home page